ATE45955T1 - In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten. - Google Patents

In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten.

Info

Publication number
ATE45955T1
ATE45955T1 AT86400057T AT86400057T ATE45955T1 AT E45955 T1 ATE45955 T1 AT E45955T1 AT 86400057 T AT86400057 T AT 86400057T AT 86400057 T AT86400057 T AT 86400057T AT E45955 T1 ATE45955 T1 AT E45955T1
Authority
AT
Austria
Prior art keywords
manufacture
optionally substituted
group
products
image
Prior art date
Application number
AT86400057T
Other languages
English (en)
Inventor
Jean-Georges Teutsch
Germain Costerousse
Vesperto Torelli
Daniel Philibert
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Application granted granted Critical
Publication of ATE45955T1 publication Critical patent/ATE45955T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT86400057T 1985-01-14 1986-01-13 In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten. ATE45955T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8500434A FR2576025B1 (fr) 1985-01-14 1985-01-14 Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
EP86400057A EP0188396B1 (de) 1985-01-14 1986-01-13 In Stellung 10 substituierte Steroide, ihre Herstellung, Zwischenprodukte in ihrer Herstellung, ihre Anwendung als Arzneimittel und pharmazeutische Zusammensetzungen,die sie enthalten

Publications (1)

Publication Number Publication Date
ATE45955T1 true ATE45955T1 (de) 1989-09-15

Family

ID=9315230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86400057T ATE45955T1 (de) 1985-01-14 1986-01-13 In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten.

Country Status (14)

Country Link
US (1) US4753932A (de)
EP (1) EP0188396B1 (de)
JP (2) JPH0772193B2 (de)
KR (1) KR930005993B1 (de)
AT (1) ATE45955T1 (de)
AU (1) AU582618B2 (de)
CA (1) CA1266466A (de)
DE (1) DE3665306D1 (de)
DK (1) DK169077B1 (de)
ES (1) ES8801509A1 (de)
FR (1) FR2576025B1 (de)
HU (1) HU196825B (de)
IE (1) IE59010B1 (de)
ZA (1) ZA86146B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639045B2 (fr) * 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2576025B1 (fr) * 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
FR2647452A1 (fr) * 1989-05-24 1990-11-30 Theramex Nouveaux 19-nor steroides 6-methyles leurs procedes d'obtention, les compositions pharmaceutiques en renfermant et leur conversion en 19-nor pregnadienes 17-substitues
DE3917274A1 (de) * 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
CN1055930C (zh) * 1994-10-08 2000-08-30 中国科学院上海有机化学研究所 一种甾体烯醇多氟烃基磺酸酯化合物及其衍生物、用途和制备方法
CN1061983C (zh) * 1996-11-29 2001-02-14 中国科学院上海有机化学研究所 一种4-三氟甲基-3-酮甾体化合物及其合成方法
CN1061987C (zh) * 1997-08-28 2001-02-14 中国科学院上海有机化学研究所 6,10－亚甲基－19－降－甾体－4－烯－3－酮化合物及其合成
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
CN1064369C (zh) * 1998-05-15 2001-04-11 中国科学院上海有机化学研究所 甾醇多氟芳酸酯、合成方法及其用途
AU4093799A (en) 1998-05-22 1999-12-13 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
DK1022636T3 (da) * 1998-07-30 2005-02-07 Hansgrohe Ag Blandingsarmatur med etgrebsbetjening
CN100400487C (zh) 1999-04-30 2008-07-09 辉瑞产品公司 糖皮质激素受体调制剂
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
JP2006508951A (ja) * 2002-11-05 2006-03-16 コーセプト セラピューティクス， インコーポレイテッド 片頭痛を処置するための方法
WO2004112720A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Antiviral compositions and methods of using the same
CN1221563C (zh) * 2003-07-16 2005-10-05 中国科学院上海有机化学研究所 16－脱氢孕烯醇酮及其同类物的生产方法
JP2008539047A (ja) 2005-04-28 2008-11-13 プロテウス バイオメディカル インコーポレイテッド ファーマインフォーマティックスシステム
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
CA2676670C (en) 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
EP2576582B1 (de) 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Behandlung von muskeldystrophie
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3335043B1 (de) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Verfahren zur differentiellen diagnose des acth-abhängigen cushing-syndroms
MX2018008849A (es) 2016-01-19 2019-01-31 Corcept Therapeutics Inc Diagnostico diferencial de sindrome de cushing ectopico.
CN107200770B (zh) * 2016-03-18 2019-11-01 华东师范大学 特拉司酮合成中环氧异构体的高效分离和循环利用方法
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
AU2021400069A1 (en) 2020-12-18 2023-07-06 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132138A (en) * 1962-02-24 1964-05-05 Roussel Uclaf Preparation of 10beta-allyl steroids and intermediates
FR1380411A (fr) * 1962-02-24 1964-12-04 Roussel Uclaf Nouveau procédé de préparation de 10 beta-allyl-stéroïdes et produits utilisésdans ce procédé
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2569408B1 (fr) * 1984-08-24 1986-10-03 Roussel Uclaf Nouveaux steroides substitues en position 10 par un radical comportant une double ou triple liaison, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
FR2576025B1 (fr) * 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
DK169077B1 (da) 1994-08-08
JPS61168029A (ja) 1986-07-29
US4753932A (en) 1988-06-28
AU582618B2 (en) 1989-04-06
ES8801509A1 (es) 1988-01-16
KR930005993B1 (ko) 1993-07-01
IE860083L (en) 1986-07-14
AU5228386A (en) 1986-07-17
FR2576025A1 (fr) 1986-07-18
HU196825B (en) 1989-01-30
DE3665306D1 (en) 1989-10-05
EP0188396A3 (en) 1986-12-10
ZA86146B (en) 1987-03-25
JPH0772193B2 (ja) 1995-08-02
DK13286D0 (da) 1986-01-13
ES550822A0 (es) 1988-01-16
KR860005832A (ko) 1986-08-13
CA1266466A (fr) 1990-03-06
HUT41047A (en) 1987-03-30
EP0188396B1 (de) 1989-08-30
FR2576025B1 (fr) 1987-01-23
DK13286A (da) 1986-07-15
JPH07316185A (ja) 1995-12-05
JP2687209B2 (ja) 1997-12-08
IE59010B1 (en) 1993-12-03
EP0188396A2 (de) 1986-07-23

Similar Documents

Publication Publication Date Title
ATE45955T1 (de) In stellung 10 substituierte steroide, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen,die sie enthalten.
NZ332608A (en) alkyl 17-alpha-dichloroacetoxy-11- beta-hydroxy-androsta-1,4-diene-3-one-17-beta-carboxylates and medicaments
DE59005254D1 (de) 24-Homo-Vitamin-D-Derivate, Verfahren zu ihrer Herstellung; diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung als Arzneimittel.
DE3880601D1 (de) Steroide mit einem 3,4- oder 6-gliedrigen spiroring in stellung 17, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen, die sie enthalten.
FR2610933B1 (fr) Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
NL7611073A (nl) Werkwijze voor het bereiden van delta15-steroiden, alsmede werkwijze voor het bereiden van een ge- neesmiddel met gestagene werking.
ATE35995T1 (de) 6,6-ethylen-15,16-methylen-3-oxo-17alpha-pregn- en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praparate.
NO172094C (no) Insekt- og middbeskyttende middel inneholdende substituerte alfa,omega-aminoalkoholderivater, disses anvendelse i slike midler samt nye alfa,omega-aminoalkoholderivater
IL72067A (en) 1-alkyl-androsta-1,4-diene-3,17-diones,processes for their preparation and pharmaceutical compositions containing the same
DE69402114T2 (de) Neue 19-Nor-Steroide mit einer 11-Beta-Phenoxysulfonamid- oder 11-Beta-Phenoxysulfonylurea-Gruppe, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie Medikamenten und pharmazeutische Präparate davon
DE2965904D1 (en) 3,20-dioxo-4,9-diene-21-hydroxy-steroid compounds, process for their preparation, their use in medicines and pharmaceutical compositions containing them
ATE72247T1 (de) Estran- und androstan-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende praeparate.
ATE430T1 (de) 16-alpha-alkylsteroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE1151T1 (de) 7-alkyl-steroidderivate, verfahren zu ihrer herstellung, ihre verwendung in arzneimitteln und pharmazeutische zusammensetzungen, die sie enthalten.
FR2422689A1 (fr) Steroides de la serie du pregnane a groupe hydroxy etherifie en position 17 et medicaments qui en contiennent
IE43985L (en) D-homosteroids
ATE18408T1 (de) 11beta-chlor-delta15-steroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATE429T1 (de) 11-methylensteroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee